• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评价猫原发性醛固酮增多症经口给予替米沙坦抑制试验的诊断价值。

Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats.

机构信息

Ecole Nationale Veterinaire d'Alfort, CHUVA, Service de médecine interne, Maisons-Alfort, Île-de-France, F-94700, France.

Centre Hospitalier Vétérinaire Aquivet, Service de médecine interne, F-33320, Eysines (Bordeaux), France.

出版信息

J Vet Intern Med. 2023 Jul-Aug;37(4):1341-1347. doi: 10.1111/jvim.16689. Epub 2023 Mar 29.

DOI:10.1111/jvim.16689
PMID:36988582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10365039/
Abstract

BACKGROUND

Development of a telmisartan-based suppression test may facilitate the diagnosis of primary hyperaldosteronism (PHA) in cats, which remains difficult today.

OBJECTIVES

To develop a telmisartan suppression test (TST) that is safe, and able to suppress aldosterone secretion in healthy cats but not in cats with PHA.

ANIMALS

Ten healthy cats and 6 cats with PHA.

METHODS

Prospective study using a placebo-controlled crossover design to investigate a TST in healthy cats, and evaluation of TST in cats with PHA. Plasma aldosterone concentration, potassium concentration, and systolic blood pressure (SBP) were measured before (T0), and 1 hour (T1) and 1.5 hours after (T1.5) PO administration of 1 mg/kg of telmisartan, 2 mg/kg of telmisartan or placebo.

RESULTS

Median age in healthy cats was 3 years old (range, 1-7). In healthy cats, a telmisartan dose of 2 mg/kg significantly decreased aldosterone concentration at T1 and T1.5 compared with T0. Placebo had no significant effect on aldosterone concentration. In cats diagnosed with PHA, a 2-mg/kg dose of telmisartan did not induce any significant change in aldosterone concentration at T1 or T1.5 compared with T0. No adverse effects of telmisartan (e.g., hyperkalemia, systemic hypotension) were observed in any cats.

CONCLUSIONS AND CLINICAL IMPORTANCE

The oral TST shows promise as a diagnostic test for the diagnosis of PHA in cats.

摘要

背景

开发一种基于替米沙坦的抑制试验可能有助于诊断原发性醛固酮增多症（PHA），目前这在猫中仍然很困难。

目的

开发一种替米沙坦抑制试验（TST），该试验既安全，又能抑制健康猫的醛固酮分泌，但不能抑制 PHA 猫的醛固酮分泌。

动物

10 只健康猫和 6 只患有 PHA 的猫。

方法

前瞻性研究采用安慰剂对照交叉设计，以调查健康猫中的 TST，并评估 PHA 猫中的 TST。在 PO 给予 1mg/kg 替米沙坦、2mg/kg 替米沙坦或安慰剂之前（T0）、1 小时（T1）和 1.5 小时（T1.5）测量血浆醛固酮浓度、钾浓度和收缩压（SBP）。

结果

健康猫的中位年龄为 3 岁（范围，1-7 岁）。在健康猫中，与 T0 相比，2mg/kg 的替米沙坦剂量可显著降低 T1 和 T1.5 时的醛固酮浓度。安慰剂对醛固酮浓度没有显著影响。在诊断为 PHA 的猫中，与 T0 相比，2mg/kg 的替米沙坦剂量在 T1 或 T1.5 时并未引起醛固酮浓度的任何显著变化。在任何猫中均未观察到替米沙坦的不良反应（例如高钾血症、全身性低血压）。

结论和临床意义

口服 TST 有望成为诊断猫 PHA 的诊断试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d8/10365039/022b306ee9af/JVIM-37-1341-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d8/10365039/520c15d8ad68/JVIM-37-1341-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d8/10365039/b1e70e70237e/JVIM-37-1341-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d8/10365039/022b306ee9af/JVIM-37-1341-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d8/10365039/520c15d8ad68/JVIM-37-1341-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d8/10365039/b1e70e70237e/JVIM-37-1341-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d8/10365039/022b306ee9af/JVIM-37-1341-g002.jpg

相似文献

1
Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats.评价猫原发性醛固酮增多症经口给予替米沙坦抑制试验的诊断价值。
J Vet Intern Med. 2023 Jul-Aug;37(4):1341-1347. doi: 10.1111/jvim.16689. Epub 2023 Mar 29.
2
Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats.前瞻性评估替米沙坦抑制试验作为猫原发性醛固酮增多症的诊断工具。
J Vet Intern Med. 2023 Jul-Aug;37(4):1348-1357. doi: 10.1111/jvim.16741. Epub 2023 May 29.
3
Evaluation of the oral fludrocortisone suppression test for diagnosing primary hyperaldosteronism in cats.评估口服氟氢可的松抑制试验在诊断猫原发性醛固酮增多症中的应用。
J Vet Intern Med. 2013 Nov-Dec;27(6):1493-9. doi: 10.1111/jvim.12216.
4
Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial.口服替米沙坦治疗猫全身性高血压的安全性和有效性：一项双盲、安慰剂对照、随机临床试验的结果。
J Vet Intern Med. 2019 Mar;33(2):478-488. doi: 10.1111/jvim.15429. Epub 2019 Mar 9.
5
Serum aldosterone and cortisol concentrations before and after suppression with fludrocortisone in cats: a pilot study.猫使用氟氢可的松抑制前后的血清醛固酮和皮质醇浓度：一项初步研究。
J Vet Diagn Invest. 2015 May;27(3):361-8. doi: 10.1177/1040638715583530. Epub 2015 Apr 21.
6
Urinary Aldosterone/Creatinine Ratio After Fludrocortisone Suppression Consistent with PHA in a Cat.氟氢可的松抑制后猫的尿醛固酮/肌酐比值与原发性醛固酮增多症相符。
J Am Anim Hosp Assoc. 2015 Sep-Oct;51(5):338-41. doi: 10.5326/JAAHA-MS-6201.
7
Feline primary hyperaldosteronism.猫原发性醛固酮增多症。
Vet Clin North Am Small Anim Pract. 2010 Mar;40(2):353-9. doi: 10.1016/j.cvsm.2009.10.006.
8
Treatment of aldosterone-secreting adrenocortical tumors in cats by unilateral adrenalectomy: 10 cases (2002-2012).猫肾上腺皮质醛固酮分泌瘤的单侧肾上腺切除术治疗：10例（2002 - 2012年）
J Vet Intern Med. 2014 Jan-Feb;28(1):137-43. doi: 10.1111/jvim.12186. Epub 2013 Dec 26.
9
Primary hyperaldosteronism: expanding the diagnostic net.原发性醛固酮增多症：扩大诊断范围。
J Feline Med Surg. 2011 Sep;13(9):641-50. doi: 10.1016/j.jfms.2011.07.017.
10
Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial.长期口服替米沙坦治疗猫高血压的疗效：一项欧洲前瞻性临床试验的结果。
J Vet Intern Med. 2019 Mar;33(2):413-422. doi: 10.1111/jvim.15394. Epub 2018 Dec 18.

引用本文的文献

1
Determination of Multi-Steroid Profiles of Cats With Hyperaldosteronism or Other Diseases: A Retrospective Study.患有醛固酮增多症或其他疾病的猫的多种类固醇谱的测定：一项回顾性研究。
J Vet Intern Med. 2025 Sep-Oct;39(5):e70209. doi: 10.1111/jvim.70209.
2
The application of telmisartan in central nervous system disorders.替米沙坦在中枢神经系统疾病中的应用。
Pharmacol Rep. 2025 Jun 19. doi: 10.1007/s43440-025-00737-2.
3
Somatic , , and Mutations in Cat Aldosterone-Secreting Tumors.猫醛固酮分泌肿瘤中的体细胞、胚系和种系突变。

本文引用的文献

1
Primary Hyperaldosteronism in Cats: An Underdiagnosed Disorder.猫原发性醛固酮增多症：一种被低估的疾病。
Vet Clin North Am Small Anim Pract. 2020 Sep;50(5):1053-1063. doi: 10.1016/j.cvsm.2020.05.007. Epub 2020 Jul 8.
2
MANAGEMENT OF ENDOCRINE DISEASE: The role of confirmatory tests in the diagnosis of primary aldosteronism.内分泌疾病管理：原发性醛固酮增多症诊断中确证试验的作用。
Eur J Endocrinol. 2019 Feb 1;180(2):R45-R58. doi: 10.1530/EJE-18-0704.
3
ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats.
Hypertension. 2024 Dec;81(12):2489-2500. doi: 10.1161/HYPERTENSIONAHA.124.23501. Epub 2024 Oct 21.
4
Long-lasting hypoaldosteronism after adrenalectomy in a cat with hyperaldosteronism.一只患有醛固酮增多症的猫肾上腺切除术后出现持久的醛固酮减少症。
JFMS Open Rep. 2024 May 12;10(1):20551169241243012. doi: 10.1177/20551169241243012. eCollection 2024 Jan-Jun.
美国兽医内科学会共识声明：犬猫系统性高血压的识别、评估及管理指南
J Vet Intern Med. 2018 Nov;32(6):1803-1822. doi: 10.1111/jvim.15331. Epub 2018 Oct 24.
4
Evaluation of orally administered telmisartan for the reduction of indirect systolic arterial blood pressure in awake, clinically normal cats.评估口服替米沙坦对清醒、临床正常猫间接收缩期动脉血压的降低作用。
J Feline Med Surg. 2019 Feb;21(2):109-114. doi: 10.1177/1098612X18761439. Epub 2018 Mar 7.
5
Aging and Adrenal Aldosterone Production.衰老与肾上腺醛固酮分泌
Hypertension. 2018 Feb;71(2):218-223. doi: 10.1161/HYPERTENSIONAHA.117.10391. Epub 2017 Dec 11.
6
Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease.替米沙坦与贝那普利长期口服治疗猫慢性肾病的疗效比较
J Vet Intern Med. 2015 Nov-Dec;29(6):1479-87. doi: 10.1111/jvim.13639. Epub 2015 Oct 16.
7
The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old.氯沙坦抑制试验在50岁以上原发性醛固酮增多症患者确诊中的价值。
J Renin Angiotensin Aldosterone Syst. 2015 Sep;16(3):587-98. doi: 10.1177/1470320313498632. Epub 2014 Jul 16.
8
Evaluation of the oral fludrocortisone suppression test for diagnosing primary hyperaldosteronism in cats.评估口服氟氢可的松抑制试验在诊断猫原发性醛固酮增多症中的应用。
J Vet Intern Med. 2013 Nov-Dec;27(6):1493-9. doi: 10.1111/jvim.12216.
9
Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate.伴有和不伴有氮血症的高血压猫的血浆肾素活性和醛固酮浓度以及对苯磺酸氨氯地平治疗的反应。
J Vet Intern Med. 2014 Jan-Feb;28(1):144-53. doi: 10.1111/jvim.12240. Epub 2013 Nov 13.
10
Captopril suppression: limitations for confirmation of primary aldosteronism.卡托普利抑制试验：原发性醛固酮增多症确诊的局限性。
J Renin Angiotensin Aldosterone Syst. 2011 Sep;12(3):326-32. doi: 10.1177/1470320310390405. Epub 2011 Jan 27.